• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.

作者信息

Shin Sanghyuk S, Modongo Chawangwa, Zetola Nicola M

机构信息

Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, California.

Botswana-UPenn Partnership, Gaborone, Botswana.

出版信息

Clin Infect Dis. 2020 Jun 24;71(1):242-243. doi: 10.1093/cid/ciz917.

DOI:10.1093/cid/ciz917
PMID:32436563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7312218/
Abstract
摘要

相似文献

1
Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.接受基于利福平的抗结核治疗的人类免疫缺陷病毒合并结核感染患者中，每日两次与每日一次多替拉韦的对比研究
Clin Infect Dis. 2020 Jun 24;71(1):242-243. doi: 10.1093/cid/ciz917.
2
Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.在 HIV 和结核病合并感染中使用多替拉韦抗逆转录病毒治疗的真实世界应用和结局：撒哈拉以南非洲的现场调查和队列研究。
J Int AIDS Soc. 2022 Jul;25(7):e25961. doi: 10.1002/jia2.25961.
3
Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.在接受利福平治疗的结核病/艾滋病病毒合并感染患者中多替拉韦的给药剂量：每日两次优于每日一次。
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e17-e20. doi: 10.1097/QAI.0000000000002352.
4
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.基于多替拉韦的抗反转录病毒疗法治疗结核分枝杆菌与人类免疫缺陷病毒合并感染患者：一项多中心、非对照、开放标签、随机试验。
Clin Infect Dis. 2020 Feb 3;70(4):549-556. doi: 10.1093/cid/ciz256.
5
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.多拉韦林每日两次给药治疗儿童 HIV 相关结核病：在开放性标签、多中心、随机、非劣效性 ODYSSEY 试验中的药代动力学和安全性研究。
Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19.
6
Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.拉替拉韦与利福平及利福布丁联用的药代动力学特征：在 HIV 与结核分枝杆菌/鸟分枝杆菌复合感染患者中的研究
Int J Infect Dis. 2022 Mar;116:147-150. doi: 10.1016/j.ijid.2022.01.001. Epub 2022 Jan 6.
7
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.每日利福平与异烟肼 1 个月方案用于结核病预防，联合双日服用度鲁特韦的抗逆转录病毒疗法。
Clin Infect Dis. 2024 Oct 15;79(4):983-989. doi: 10.1093/cid/ciae183.
8
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).利福平高剂量治疗耐多药结核病-艾滋病毒合并感染患者的药代动力学、安全性/耐受性和疗效：基于依非韦伦或多替拉韦的抗逆转录病毒治疗的开放性、二期临床试验方案（SAEFRIF）。
Trials. 2020 Feb 13;21(1):181. doi: 10.1186/s13063-020-4132-7.
9
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.利福平治疗婴儿中多替拉韦的每日 2 次给药：EMPIRICAL 试验的药代动力学子研究。
Clin Infect Dis. 2024 Mar 20;78(3):702-710. doi: 10.1093/cid/ciad656.
10
Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.多替拉韦为基础的抗反转录病毒治疗方案治疗结核/艾滋病毒合并感染患者的临床和病毒学结局：来自博茨瓦纳的规划经验。
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):111-115. doi: 10.1097/QAI.0000000000002126.

引用本文的文献

1
Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.在接受基于多替拉韦的一线抗逆转录病毒治疗的初治整合酶抑制剂初治队列中，合并症及伴随用药情况。
Pan Afr Med J. 2024 Mar 25;47:137. doi: 10.11604/pamj.2024.47.137.40726. eCollection 2024.

本文引用的文献

1
Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.多替拉韦为基础的抗反转录病毒治疗方案治疗结核/艾滋病毒合并感染患者的临床和病毒学结局：来自博茨瓦纳的规划经验。
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):111-115. doi: 10.1097/QAI.0000000000002126.
2
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.推进新型结核病治疗方案的研发：转化医学与临床药理学及微生物学的重要作用。
PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul.
3
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.多替拉韦 100 毫克每日一次与利福平合用的药代动力学。
Int J Antimicrob Agents. 2019 Aug;54(2):202-206. doi: 10.1016/j.ijantimicag.2019.04.009. Epub 2019 Apr 16.
4
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.每日两次给予利福平或每日一次给予利福布丁时，HIV 整合酶抑制剂多替拉韦的安全性、耐受性和药代动力学：健康受试者中的一项 1 期研究结果。
J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7. doi: 10.1097/QAI.0b013e318276cda9.